Similar Posts
Moderna Dips on Q2 Earnings But Can It Rip on a Short Squeeze?
$90.15 +3.31 (+3.81%) (As of 03:08 PM ET) 52-Week Range $62.55 ▼ $170.47 Price Target $124.07 Biotechnology company Moderna Inc. NASDAQ: MRNA stock rocked investors with a 30% drop following its second-quarter 2024 earnings release. The company disappointed investors when it revised its respiratory franchise revenue forecast lower by half a billion dollars. However, shares were…
Sagility: Non-Linear Deal
Source: Investor Presentation of Sagility Ltd Source link
Business News Live, Share Market News – Read Latest Finance News, IPO, Mutual Funds News – The Economic Times
Mutual funds increased their holdings in several mid and large-cap companies during the December ’25 quarter, with stakes exceeding 20% in 11 stocks. While many of these stocks have delivered negative returns since January ’26, the higher institutional ownership indicates continued long-term confidence among fund managers. Source link
Nova FI Trader | Part 1: What It Is and Why It Is Free
⏳ 29 Days Left | Nova Launch Pricing Ends May 20, 2026 Nova is changing. 47 EAs cut. 3 kept. For the next 29 days, two EAs are available at the lowest price they will ever be. Nova DNA Trader – $69 until May 20 | Nova PAX Trader – $49 until May 20 After May 20,…
What’s Going On, Big Tech? | From the Mind of the Gorilla
Even the biggest giants take a stumble now and then… The latest earnings reports from three of the biggest names in tech – Microsoft, Meta, and Tesla – were a mixed bag. What does this mean? It proves that no company – no matter how dominant – is immune to the occasional rough patch. But…
